Investment analysts at Piper Sandler began coverage on shares of Oncobiologics (NASDAQ:OTLK – Get Free Report) in a report released on Thursday, Briefing.com reports. The firm set an “overweight” rating on the stock.
A number of other brokerages have also recently commented on OTLK. BTIG Research reiterated a “buy” rating and issued a $4.00 target price on shares of Oncobiologics in a research report on Friday, August 14th. Wall Street Zen cut shares of Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. HC Wainwright lifted their target price on shares of Oncobiologics to $1.60 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncobiologics in a research report on Tuesday, November 10th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Oncobiologics presently has a consensus rating of “Hold” and an average target price of $4.90.
Read Our Latest Analysis on OTLK
Oncobiologics Stock Up 13.1%
Shares of NASDAQ:OTLK opened at $0.41 on Thursday. The stock has a market cap of $99.30 million, a PE ratio of -0.53 and a beta of 0.75. The company’s fifty day moving average is $0.55 and its 200 day moving average is $0.66. Oncobiologics has a 52 week low of $0.16 and a 52 week high of $2.54.
Institutional Trading of Oncobiologics
An institutional investor recently bought a new position in Oncobiologics stock. NewEdge Advisors LLC bought a new position in Oncobiologics, Inc. (NASDAQ:OTLK – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 16,722 shares of the company’s stock, valued at approximately $27,000. Institutional investors own 11.20% of the company’s stock.
Oncobiologics Company Profile
Oncobiologics, Inc. changed its name to Outlook Therapeutics, Inc. in 2018 and trades under the symbol OTLK. The biotechnology company focuses on developing and commercializing treatments for eye diseases. Its lead product, Lytenava (bevacizumab gamma), is an ophthalmic formulation of bevacizumab developed to treat neovascular age-related macular degeneration, also known as wet AMD. The company has pursued regulatory approvals and commercialization of the treatment in the United States and Europe.
Read More
- Five stocks we like better than Oncobiologics
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.
